Nonetheless, given the critical role of de-regulated NF-κB activity in colorectal cancer initiation and progression, it is extremely likely that this repression contributes significantly to the anti-tumour effect of the agents in humans. The gene discussed is NFKB1; the disease is colorectal cancer.